longterm
protect
sar
coronaviru
infect
confer
singl
immun
attenu
vsvbase
vaccin
virolog
difficult
obtain
regulatori
approv
vaccin
base
live
virus
construct
replicationdefect
singlecycl
vsv
vector
replac
vsv
glycoprotein
g
gene
sarscov
gene
viru
abl
infect
cell
pseudotyp
vsv
g
protein
measur
effect
immun
singlecycl
vaccin
mice
found
vaccin
given
intramuscularli
induc
neutral
antibodi
respons
sarscov
approxim
tenfold
greater
requir
protect
sarscov
infect
significantli
greater
gener
replicationcompet
vector
express
sarscov
protein
given
rout
result
along
earlier
studi
show
potent
induct
tcell
respons
singlecycl
vector
indic
vector
excel
altern
liveattenu
vsv
sar
vaccin
base
replicationdefect
recombin
vesicular
stomat
viru
potent
one
base
replicationcompet
vector
introduct
sar
sever
acut
respiratori
syndrom
emerg
fall
china
soon
caught
world
attent
quickli
spread
countri
end
world
health
organ
report
probabl
case
sar
fifth
occur
health
care
worker
overal
fatal
rate
peopl
age
rate
exceed
http
wwwwho
intcsrsarsenwhoconsensuspdf
peiri
et
al
etiolog
agent
quickli
identifi
coronaviru
cov
ksiazek
et
al
kb
genom
sequenc
reveal
common
coronaviru
genom
organ
marra
et
al
rota
et
al
six
major
open
read
frame
identifi
four
encod
major
structur
protein
spike
membran
nucleocapsid
n
envelop
e
n
e
involv
viral
assembl
bud
major
glycoprotein
bind
cellular
receptor
ace
mediat
entri
class
viral
fusion
mechan
bosch
et
al
report
case
sar
sinc
howev
sourc
sarscov
still
exist
anim
carrier
viru
includ
himalayan
palm
civet
raccoon
dog
bat
identifi
guan
et
al
lau
et
al
li
et
al
sever
case
laboratoryacquir
sar
also
report
sarscov
erad
still
potenti
human
infect
sar
vaccin
may
import
control
futur
outbreak
sever
experiment
vaccin
construct
test
includ
dna
vaccin
protein
subunit
vaccin
inactiv
sarscov
vaccin
recombin
viral
vaccin
gillimross
subbarao
sarscov
glycoprotein
use
antigen
develop
sar
vaccin
target
viru
neutral
antibodi
previous
report
develop
experiment
vsvbase
sar
vaccin
vsv
vesicular
stomat
viru
neg
strand
rna
viru
belong
viru
famili
rhabdovirida
kapadia
et
al
attenu
vector
deriv
vsv
use
extens
experiment
vaccin
candid
daddariodicaprio
et
al
b
egan
et
al
geisbert
et
al
jone
et
al
kahn
et
al
natuk
et
al
palin
et
al
ramsburg
et
al
reuter
et
al
robert
et
al
robert
et
al
robert
et
al
rose
et
al
schlereth
et
al
schlereth
et
al
induc
strong
antibodi
cellular
immun
respons
except
rural
popul
central
south
america
neglig
seroposit
vsv
human
popul
reif
et
al
make
attract
candid
human
vaccin
popul
preexist
immun
vsv
nonendem
vsv
serotyp
vector
use
vsv
also
grow
high
titer
cell
line
approv
vaccin
product
initi
studi
kapadia
et
al
show
vsv
recombin
express
sarscov
protein
capabl
gener
neutral
antibodi
sarscov
mice
furthermor
immun
mice
protect
sarscov
challeng
also
show
humor
respons
suffici
protect
current
studi
gener
test
effect
vsv
recombin
capabl
undergo
one
round
infect
lack
gene
encod
vsv
glycoprotein
g
use
replicationdefici
vector
would
overcom
complex
regulatori
issu
relat
approv
liveviru
vector
use
human
howev
product
vector
would
requir
qualif
celllin
express
vsv
g
plasmid
dna
base
complement
furthermor
singlecycl
viral
vaccin
would
allevi
concern
potenti
risk
relat
use
live
viral
vector
individu
weaken
immun
system
order
evalu
vector
sar
vaccin
candid
also
develop
sarscov
neutral
assay
use
pseudotyp
vsv
recombin
express
green
fluoresc
protein
order
recov
singlecycl
vsv
recombin
encod
protein
sarscov
vsv
glycoprotein
g
gene
plasmid
express
vsv
antigenom
replac
gene
encod
sarscov
fig
result
plasmid
use
recov
viru
cell
express
vsv
g
g
requir
viru
entri
vsv
recombin
lack
g
gene
must
complement
g
order
produc
infecti
particl
virus
lack
vsv
g
gene
egfp
gene
insert
first
posit
genom
rna
sequenc
shown
antigenom
sens
c
cell
infect
either
wt
vsv
cell
fix
sarscov
visual
indirect
immunofluoresc
fluoresc
imag
shown
left
differenti
interfer
contrast
dic
imag
shown
right
lysat
metabol
label
cell
infect
wt
vsv
lane
vsv
lane
lane
analyz
sdspage
lysat
also
treat
pngase
f
remov
nlink
glycan
protein
lane
complement
g
infect
cell
singl
cycl
propag
absenc
complement
g
protein
use
infect
cell
observ
singl
infect
cell
viru
spread
consist
absenc
encod
vsv
g
protein
determin
protein
express
recombin
examin
cell
use
indirect
immunofluoresc
microscopi
cell
infect
wild
type
wt
vsv
fix
incub
serum
sarscovinfect
mous
secondari
alexa
fluor
antimous
antibodi
use
visual
confoc
microscopi
fig
found
sarscov
protein
express
cell
surfac
indic
strong
surfac
fluoresc
signal
visibl
cell
infect
control
cell
infect
wt
vsv
evalu
viral
protein
express
infect
cell
wt
vsv
vsv
kapadia
et
al
metabol
label
cell
methionin
lysat
radiolabel
cell
analyz
sdspage
vsv
infect
shut
host
protein
synthesi
five
vsv
protein
l
g
n
p
readili
seen
without
immunoprecipit
fig
lane
vsvsinfect
cell
express
sarscov
protein
addit
five
vsv
protein
fig
lane
cell
express
vsv
protein
except
g
fig
lane
highli
glycosyl
protein
also
treat
lysat
pngase
f
remov
glycan
order
character
digest
migrat
faster
gel
fig
lane
chang
consist
remov
predict
glycan
kapadia
et
al
low
level
protein
sarscov
incorpor
vsv
particl
data
shown
possibl
protein
might
mediat
infect
absenc
g
determin
protein
could
mediat
infect
infect
vero
cell
cell
express
sarscov
receptor
li
et
al
gpseudotyp
use
immunofluoresc
microscopi
assay
observ
vsv
n
protein
express
saw
singl
infect
cell
h
observ
infect
cell
h
despit
near
confluent
monolay
live
vero
cell
result
indic
capabl
second
round
infect
addit
passag
cell
yield
progeni
lack
vsv
g
attempt
infect
vero
cell
viru
stock
even
though
could
detect
protein
noncompl
virion
western
blot
observ
infect
vero
cell
particl
result
indic
protein
present
virion
capabl
mediat
vsv
entri
tissu
cultur
consist
report
result
show
fulllength
protein
encod
capabl
mediat
infect
pseudotyp
vsv
fukushi
et
al
determin
abl
replic
vivo
without
vsv
g
inocul
mice
intramuscularli
im
noncompl
infect
viru
anticip
might
detect
immun
respons
protein
measur
sarscov
neutral
antibodi
respons
measur
replic
control
possibl
immun
respons
protein
surfac
particl
inoculum
also
administ
uvinactiv
noncompl
addit
control
immun
two
group
mice
either
gcomplement
uvinactiv
gcomplement
dose
pfu
plaqu
form
unit
gcomplement
use
equival
particl
dose
noncompl
viru
assess
amount
n
protein
viru
prepar
determin
western
blot
one
month
inocul
serum
collect
anim
sarscov
neutral
titer
determin
gcomplement
anim
gener
measur
neutral
titer
sarscov
fig
averag
anim
remain
group
includ
inocul
noncompl
made
measur
neutral
antibodi
respons
even
antibodi
dilut
indic
signific
replic
occur
uvinactiv
gcomplement
induc
neutral
antibodi
respons
indic
one
round
replic
essenti
respons
also
assess
immun
respons
vsv
vector
anim
use
serum
anim
stain
vsvinfect
cell
observ
vsv
n
express
immunofluoresc
microscopi
anim
immun
live
gcomplement
antibodi
respons
n
anim
inocul
noncompl
detect
respons
vsv
support
idea
infecti
anim
without
vsv
g
order
test
potenti
singlecycl
vsv
recombin
sar
vaccin
conduct
studi
includ
five
group
mice
first
group
includ
three
control
mice
receiv
wt
vsv
intranas
second
group
three
mice
inocul
wt
vsv
im
third
group
six
mice
immun
vsv
administ
fourth
group
six
mice
receiv
vsv
im
last
group
five
mice
vaccin
im
singl
vaccin
dose
pfu
administ
serum
collect
mice
week
postimmun
verifi
mice
infect
vector
measur
vsv
neutral
antibodi
titer
serum
individu
mice
five
week
postinfect
fig
vsv
g
protein
target
vsv
neutral
antibodi
kelley
et
al
mice
made
measur
neutral
antibodi
titer
vsv
consist
success
infect
wt
vsv
administ
produc
highest
vsv
neutral
titer
mean
titer
consist
previou
result
kapadia
et
al
wt
vsv
given
im
vsv
given
either
im
produc
mean
vsv
neutral
titer
group
produc
lower
vsv
neutral
titer
mean
consist
fact
viru
encod
vsv
g
protein
carri
g
protein
particl
gener
complement
vsv
g
result
indic
mice
effect
inocul
humor
respons
sarscov
protein
suffici
protect
sarscov
infect
want
determin
sarscov
neutral
antibodi
titer
serum
mice
studi
previou
studi
use
direct
neutral
sarscov
determin
sarscov
neutral
titer
order
circumv
level
biocontain
requir
assay
develop
valid
assay
use
viru
express
egfp
complement
sarscov
protein
target
sarscov
neutral
antibodi
first
gener
vsv
recombin
genom
viru
fig
four
vsv
gene
n
p
l
egfp
gene
first
posit
vsv
genom
promot
maxim
egfp
express
next
insert
gene
tag
sarscov
protein
cytoplasm
tail
replac
ha
epitop
tag
mammalian
express
vector
pcagg
niwa
et
al
delet
tail
requir
infect
context
pseudotyp
virus
fukushi
et
al
girogl
et
al
moor
et
al
plasmid
transfect
cell
transfect
cell
express
protein
infect
complement
vsv
g
viru
adsorb
h
cell
wash
three
time
pb
order
remov
input
particl
media
replac
infect
allow
continu
h
result
pseudotyp
viru
present
media
collect
cell
next
determin
pseudotyp
could
use
assay
sarscov
neutral
antibodi
incub
pseudotyp
viru
antiserum
mice
inocul
either
wt
vsv
neutral
antibodi
direct
vsv
g
vsv
neutral
antibodi
vsv
sarscov
sarscov
antibodi
sarscov
dilut
ascertain
antibodi
capabl
neutral
pseudotyp
viru
use
pseudotyp
vsv
g
control
measur
neutral
antibodi
react
vsv
g
follow
onehour
incub
virusserum
mixtur
transfer
monolay
vero
cell
express
sarscov
receptor
ace
li
et
al
cell
incub
h
fix
paraformaldehyd
determin
infect
observ
egfp
express
use
fluoresc
microscopi
infect
vero
cell
pseudotyp
neutral
antibodi
vsv
neutral
antibodi
vsv
contain
antibodi
vsv
sarscov
contain
antibodi
contrast
neutral
antibodi
sarscov
neutral
antiserum
vsv
vsv
fig
result
show
neutral
spseudotyp
viru
specif
antibodi
sarscov
next
compar
sensit
neutral
assay
standard
assay
use
serum
standard
assay
previous
direct
sarscov
neutral
assay
use
sera
mice
fig
specif
neutral
anti
antibodi
pseudotyp
either
vsv
g
protein
incub
antiserum
mice
immun
wt
vsv
vsv
sarscov
indic
pseudotyp
transfer
vero
cell
infect
determin
egfp
express
fluoresc
imag
differenti
interfer
contrast
dic
imag
shown
field
immun
either
wt
vsv
vsv
sarscov
previou
sar
vaccin
studi
kapadia
et
al
sarscov
neutral
antibodi
titer
sera
determin
incub
viru
serial
dilut
sera
virusserum
mixtur
transfer
monolay
vero
cell
infect
determin
observ
egfp
express
fluoresc
microscopi
h
infect
titer
defin
highest
dilut
complet
neutral
detect
neutral
activ
serum
mice
vaccin
wt
vsv
titer
serum
sampl
vsvsand
sarscovinocul
mice
determin
respect
pseudotyp
assay
titer
sera
direct
assay
furthermor
sera
mice
abl
control
sarscov
infect
upon
challeng
sinc
antibodi
respons
suffici
protect
sarscov
bisht
et
al
kapadia
et
al
yang
et
al
titer
neutral
titer
low
indic
protect
use
neutral
assay
measur
neutral
antibodi
titer
serum
mice
current
studi
fig
sarscovneutr
antibodi
detect
anim
infect
wt
vsv
littl
variabl
individu
mice
within
group
three
time
point
measur
fig
b
c
notabl
anim
made
neutral
antibodi
titer
consider
greater
titer
determin
previous
protect
sarscov
challeng
anim
infect
vsv
produc
robust
respons
mean
titer
five
week
postvaccin
fig
level
drop
nine
week
postvaccin
group
immun
also
made
strong
antibodi
respons
averag
titer
approxim
time
point
test
respons
twofold
greater
seen
group
immun
im
replicationcompet
vsv
differ
statist
signific
week
postimmun
p
mannwhitney
test
similar
trend
previous
report
singlecycl
vsv
vector
express
hiv
env
protein
gener
gener
better
tcell
respons
hiv
env
replicationcompet
vsv
vector
express
hiv
env
administ
im
though
differ
statist
signific
regulatori
approv
use
replicationcompet
vsvbase
vaccin
vector
human
slow
concern
potenti
pathogenesi
therefor
develop
singlecycl
vsvbase
vector
lack
vsv
g
gene
infect
cell
produc
infecti
particl
schnell
et
al
report
replicationdefect
vector
express
sarscov
protein
highli
effect
gener
sarscov
neutral
antibodi
anim
given
im
even
better
replicationcompet
vsv
vector
express
sarscov
given
rout
concern
singlecycl
vaccin
vector
describ
might
abl
mediat
multipl
round
infect
protein
incorpor
virion
howev
detect
infect
nongcompl
particl
cell
express
sarscov
receptor
furthermor
inocul
mice
noncompl
pseudotyp
particl
saw
immun
respons
vsv
n
indic
signific
infect
occur
other
also
report
fulllength
sarscov
abl
mediat
entri
vsv
found
delet
carboxytermin
tail
requir
smediat
entri
fukushi
et
al
tail
also
inhibitori
mediat
entri
retrovirus
girogl
et
al
moor
et
al
like
tail
sequenc
neg
regul
membran
fusion
activ
protein
sarscov
virion
protein
function
activ
protein
membran
fusion
activ
consist
earlier
report
found
fulllength
protein
would
pseudotyp
gener
infecti
virion
protein
cytoplasm
tail
delet
replac
ha
tag
pseudotyp
effect
taken
togeth
evid
indic
singlecycl
vector
strength
immun
respons
protein
express
replicationcompet
vsv
vector
given
correl
posit
abil
replic
spread
system
simon
et
al
singlecycl
vector
spread
system
simon
et
al
rel
poor
vector
given
yet
gener
strong
immun
respons
given
im
studi
report
therefor
test
singlecycl
vector
intramuscular
rout
found
one
dose
vector
abl
gener
high
level
sarscov
neutral
antibodi
titer
neutral
titer
least
tenfold
greater
requir
complet
protect
sarscov
replic
mice
previou
studi
kapadia
et
al
twofold
greater
induc
replicationcompet
vsv
given
im
antibodi
respons
suffici
control
sarscov
infect
kapadia
et
al
yang
et
al
titer
predict
protect
mous
model
although
sarscov
neutral
antibodi
titer
obtain
mice
immun
replicationcompet
vsv
higher
averag
titer
obtain
anim
immun
im
also
know
replicationcompet
vector
spread
system
vaccin
rout
simon
et
al
viru
replic
lung
caus
viremia
spread
multipl
organ
widespread
dissemin
vector
could
also
rais
safeti
concern
explain
greater
potenc
singlecycl
vector
rel
replicationcompet
vector
given
im
first
evid
replicationcompet
singlecycl
vector
effect
singlecycl
vector
given
im
ian
simon
unpublish
result
second
singlecycl
vector
may
effect
greater
express
protein
absenc
upstream
g
protein
gene
transcript
attenu
iverson
rose
remov
g
gene
lead
greater
transcript
express
sarscov
gene
order
evalu
possibl
quantifi
express
treat
pngase
f
vsv
rel
np
express
gel
shown
fig
found
express
approxim
protein
vsv
lastli
also
possibl
express
g
protein
replicationcompet
vector
compet
protein
antibodi
respons
result
report
along
earlier
studi
show
potent
induct
cellular
immun
respons
singlecycl
vector
indic
singlecycl
vector
excel
altern
liveattenu
vsv
vaccin
vector
warrant
develop
construct
sarscov
gene
amplifi
pvsvsar
kapadia
et
al
pcr
use
follow
primer
pcr
product
digest
mlui
nhei
site
underlin
ligat
purifi
bp
fragment
result
digest
schnell
et
al
enzym
plasmid
express
egfp
first
posit
genom
gener
digest
hpai
xbai
vector
fragment
purifi
ligat
kb
fragment
result
digest
robert
et
al
enzym
result
plasmid
design
pcaagssar
made
pcr
amplif
sarscov
gene
primer
replac
region
encod
last
residu
carboxytermin
tail
sequenc
encod
ha
epitop
tag
follow
primer
use
sequenc
encod
ha
tag
shown
bold
result
pcr
product
digest
xhoi
nhei
site
underlin
ligat
pcaag
niwa
et
al
also
digest
enzym
construct
pcaagsg
previous
describ
okuma
et
al
virus
recov
plasmid
previous
describ
method
schnell
et
al
recov
viral
supernat
transfer
onto
cell
transfect
describ
pcaagsg
okuma
et
al
supernat
contain
complement
g
collect
h
virus
titer
bhkg
cell
schnell
et
al
use
standard
plaqu
assay
obtain
pseudotyp
protein
transfect
cell
pcaagssar
describ
transfect
cell
infect
recov
complement
vsv
g
one
hour
infect
input
viru
remov
cell
wash
time
phosphat
buffer
salin
pb
dmem
contain
fb
ad
cell
media
contain
complement
collect
h
viru
titer
vero
cell
assess
number
cell
express
egfp
vsvsar
vsv
kapadia
et
al
wt
vsv
lawson
et
al
recoveri
previous
describ
noncompl
obtain
infect
cell
moi
h
cell
wash
time
pb
remov
input
viru
dmem
fb
ad
cell
incub
overnight
media
collect
subject
ultracentrifug
h
order
concentr
viru
nine
microgram
dna
dilut
ml
optimem
invitrogen
carlsbad
ca
lipofectamin
reagent
invitrogen
carlsbad
ca
also
dilut
ml
optimem
dna
lipofectamin
mixtur
combin
incub
min
room
temperatur
cell
cell
plate
h
earlier
wash
pb
ml
optimem
ad
dnalipofectamin
ad
cell
incub
h
ml
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
ad
left
overnight
next
morn
media
replac
dmem
contain
fb
transfect
allow
continu
h
addit
dnalipofectamin
mixtur
cell
infect
wt
vsv
vsv
multipl
infect
moi
h
cell
wash
twice
methioninefre
dmem
incub
methionin
ml
methioninefre
dmem
min
cell
wash
twice
pb
solubil
deterg
solut
nonidet
deoxychol
mm
trishcl
ph
mm
edta
lysat
analyz
sdspage
protein
sampl
treat
peptid
nglycosidas
pngase
f
new
england
biolab
beverli
accord
manufactur
instruct
indirect
immunofluoresc
microscopi
cell
plate
glass
coverslip
infect
either
wt
vsv
h
cell
wash
twice
pb
fix
paraformaldehyd
cell
wash
twice
pb
contain
mm
glycin
incub
serum
sarscov
infect
mous
dilut
coverslip
wash
twice
pbsglycin
incub
alexa
fluor
goat
antimous
igg
molecular
probe
eugen
dilut
cell
wash
twice
pbsglycin
mount
slide
cell
imag
use
biorad
radianc
confoc
scan
system
nikon
elips
microscop
planapochromat
object
fluoresc
microscopi
visual
egfp
perform
nikon
microphot
fx
microscop
equip
planapochromat
object
epifluoresc
spot
digit
camera
tenweekold
balbc
mice
charl
river
laboratori
use
studi
singl
intranas
inocul
plaqu
form
unit
pfu
wt
vsv
vsv
administ
volum
anim
lightli
anesthet
isofluran
baxter
deerfield
il
dilut
propylen
glycol
vv
singl
intramuscular
inocul
pfu
wt
vsv
vsv
administ
volum
hind
leg
muscl
vsv
neutral
titer
defin
highest
dilut
serum
complet
neutral
infect
pfu
vsv
cell
assay
describ
previous
order
measur
sarscov
neutral
antibodi
serum
first
incub
two
monoclon
antibodi
lefrancoi
lyle
dilut
per
antibodi
h
neutral
potenti
infect
due
residu
vsv
g
may
incorpor
particl
pseudotyp
protein
serum
sampl
serial
dilut
dmem
contain
fb
approxim
infecti
pseudotyp
particl
ad
serum
dilut
final
volum
mixtur
incub
hour
dilut
transfer
monolay
vero
cell
grown
plate
h
dmem
fb
ad
well
cell
incub
h
infect
determin
visual
egfp
express
use
olympu
microscop
equip
epifluoresc
dilut
measur
duplic
titer
determin
highest
dilut
duplic
show
infect
